Pod Save America Hosts Call on Democrats to Cut All Israel Military Aid, No Longer Accept AIPAC Funding
Jews, Israelis Targeted in Austria Amid Surge in Antisemitic Incidents; Local Jewish Community Calls for Action
‘All of Our Strength’: Over 1,000 Pro-Israel Activists Gather in DC for Solidarity Conference
‘Devastated’: Wesley LePatner, Killed in Manhattan Mass Shooting, Was a Jewish Communal, Philanthropic Leader
Sen. Angus King Vows to No Longer Vote for Israel Military Aid Until Gaza Conditions Improve
Europe Won’t Pressure Israel to ‘Commit Suicide’ Amid Gaza Backlash, Palestinian State Push, Says Israeli FM
Israel’s National Soccer Coach Attacked in Athens Before Soccer Fans Chant ‘F–K Israel, Free Palestine’ at Match
New York Judge Sentences Neo-Nazi to 5 Years for Livestreaming Bomb Threats Against Jewish Hospitals
US Pressures Lebanon to Issue Cabinet Decision to Disarm Hezbollah Before Talks Continue
UK Plans to Recognize Palestinian State in September Unless Israel Meets Conditions, Starmer Says
Israeli Researchers Develop New Test That Detects Risk of Breast or Ovarian Cancer
Error: Contact form not found.
by Zach Pontz
Breast cancer awareness ribbon. Photo: Wikipedia.
Israeli researchers have developed a test that can predict if healthy women are at a significant risk of developing breast or ovarian cancer. Using a blood test, the researchers from Hadassah Medical Center were able to identify the presence of a harmful mutation, which may trigger those types of cancers in women.
The test, which was developed using a technology called gene expression profiling, is able to predict the presence of harmful BRCA1 and BRCA2 mutations in otherwise healthy women.
“This novel technology aims to provide a layer of information regarding the cell functionality aspect of BRCA mutations that could greatly enhance the doctor’s ability to identify high-risk carriers,” explains Dr. Asher Salmon, who led the research team.
The new test will require less resources. Until the present the only means of detecting such mutations was by doing a full gene sequencing, but Dr. Salmon said the process is “expensive, time consuming and, in many cases, lacks clear and decisive information for making a clinical decision.”
According to Salmon, the test can reveal many different types of harmful mutations. “In societies where gene sequencing is not feasible, this test can substitute for it with a very high accuracy rate,” Salmon explains.
The Israeli research team reported their findings in Cancer Prevention Research, a journal of the American Association for Cancer Research.
